Next Article in Journal
In Vitro Fecal Fermentation of High Pressure-Treated Fruit Peels Used as Dietary Fiber Sources
Next Article in Special Issue
Two Approaches for Evaluating the Effects of Galangin on the Activities and mRNA Expression of Seven CYP450
Previous Article in Journal
Tetracycline Residues in Bovine Muscle and Liver Samples from Sicily (Southern Italy) by LC-MS/MS Method: A Six-Year Study
Previous Article in Special Issue
Identification and Extraction Optimization of Active Constituents in Citrus junos Seib ex TANAKA Peel and Its Biological Evaluation
Open AccessArticle

Bioactivity Determination of a Therapeutic Recombinant Human Keratinocyte Growth Factor by a Validated Cell-based Bioassay

by Wenrong Yao 1,2,†, Ying Guo 1,†, Xi Qin 1,†, Lei Yu 1, Xinchang Shi 1, Lan Liu 1, Yong Zhou 1, Jinpan Hu 1, Chunming Rao 1,* and Junzhi Wang 1,*
1
National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China
2
Institutes of Process Engineering, Chinese Academy of Sciences, 1 North 2nd Street, Zhongguancun, Haidian District, Beijing 100190, China
*
Authors to whom correspondence should be addressed.
They contributed equally to this work.
Academic Editors: In-Soo Yoon and Hyun-Jong Cho
Molecules 2019, 24(4), 699; https://doi.org/10.3390/molecules24040699
Received: 19 January 2019 / Revised: 12 February 2019 / Accepted: 13 February 2019 / Published: 15 February 2019
(This article belongs to the Special Issue Method Development and Validation in Food and Pharmaceutical Analysis)
The therapeutic recombinant human keratinocyte growth factor 1 (rhKGF-1) was approved by the FDA for oral mucositis resulting from hematopoietic stem cell transplantation for hematological malignancies in 2004. However, no recommended bioassay for rhKGF-1 bioactivity has been recorded in the U.S. Pharmacopoeia. In this study, we developed an rhKGF-1-dependent bioassay for determining rhKGF-1 bioactivity based on HEK293 and HaCat cell lines that stably expressed the luciferase reporter driven by the serum response element (SRE) and human fibroblast growth factor receptor (FGFR2) IIIb. A good responsiveness to rhKGF-1 and rhKGF-2 shared by target HEK293/HaCat cell lines was demonstrated. Our stringent validation was completely focused on specificity, linearity, accuracy, precision, and robustness according to the International Council for Harmonization (ICH) Q2 (R1) guidelines, AAPS/FDA Bioanalytical Workshop and the Chinese Pharmacopoeia. We confirmed the reliability of the method in determining rhKGF bioactivity. The validated method is highly timesaving, sensitive, and simple, and is especially valuable for providing information for quality control during the manufacture, research, and development of therapeutic rhKGF. View Full-Text
Keywords: rhKGF-1; rhKGF-2; bioactivity; cell-based bioassay; method validation rhKGF-1; rhKGF-2; bioactivity; cell-based bioassay; method validation
Show Figures

Graphical abstract

MDPI and ACS Style

Yao, W.; Guo, Y.; Qin, X.; Yu, L.; Shi, X.; Liu, L.; Zhou, Y.; Hu, J.; Rao, C.; Wang, J. Bioactivity Determination of a Therapeutic Recombinant Human Keratinocyte Growth Factor by a Validated Cell-based Bioassay. Molecules 2019, 24, 699.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop